Lantheus (NASDAQ:LNTH) Reaches New 12-Month High – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $104.00 and last traded at $102.8650, with a volume of 268369 shares traded. The stock had previously closed at $102.82.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 price target on shares of Lantheus in a research report on Thursday, May 7th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Mizuho raised their price objective on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. Finally, Truist Financial reaffirmed a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Down 2.0%

The business’s 50 day moving average price is $87.50 and its 200 day moving average price is $74.77. The firm has a market cap of $6.56 billion, a price-to-earnings ratio of 24.30 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter last year, the company earned $1.53 EPS. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 4.41 EPS for the current year.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently added to or reduced their stakes in LNTH. Hantz Financial Services Inc. grew its stake in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares during the period. Western Wealth Management LLC acquired a new stake in Lantheus during the 1st quarter worth $25,000. Smartleaf Asset Management LLC boosted its stake in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC boosted its stake in Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the last quarter. Finally, Osterweis Capital Management Inc. acquired a new stake in Lantheus during the 2nd quarter worth $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.